Raphael Pharmaceutical (RAPH) Non-Current Debt (2024 - 2025)
Raphael Pharmaceutical (RAPH) reported Non-Current Debt of $34000.0 for Q4 2025, down 85.09% on a YoY basis from $228000.0 in Q4 2024, and down 85.09% sequentially from $228000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Non-Current Debt (2024 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 2 years of Non-Current Debt data on file, last reported at $34000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt fell 85.09% year-over-year to $34000.0; the trailing twelve-month figure through Dec 2025 stood at $34000.0 (down 85.09% YoY), and the FY2025 full-year result was $34000.0, down 85.09% from the prior year.
- Non-Current Debt fell to $34000.0 in Q4 2025, from $228000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $228000.0 in Q4 2024 to a low of $34000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 228,000.00 |